We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » DIA 2021 Annual Meeting: FDA ‘Integrated Review’ Was Central to Inmazeb Approval
DIA 2021 Annual Meeting: FDA ‘Integrated Review’ Was Central to Inmazeb Approval
Regeneron’s successful Biologics License Application (BLA) for its Ebola treatment Inmazeb last October was an example of the FDA’s new integrated-review process in action, an agency official said yesterday at the Drug Information Association’s annual meeting.